NEW YORK (TheStreet) -- Novagen (NVGN) shares spiked 24.72% to $5.62 in trading on Thursday after the Australia-based biotechnology company revealed that studies of its experimental drug, Anisina, showed signs of what could be a breakthrough in melanoma treatment.

Anisina was successful in killing melanoma cells irrespective of their mutational status. This is significant because melanoma is associated with a variety of mutations, including those with the BRAF gene which occurs in about half of melanoma patients, that do not have targeted therapy options.

The BRAF gene has multiple treatment options while other mutations do not, but the study conducted by The University of Queensland Diamantina Institute suggests that Anisina treats the disease regardless of the type of mutation.

"These results support our belief that Anisina has the potential to become one of the most widely used anti-cancer drugs across the full spectrum of cancer. In conjunction with our clinical advisors, we have a clinical strategy laid out which we intend to prosecute all the way through to achieving regulatory approval," said CEO Graham Kelly, PhD.

NVGN Chart NVGN data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

More from Markets

IBM Shares Jump After Beating Earnings and Guidance Expectations

IBM Shares Jump After Beating Earnings and Guidance Expectations

3 Things to Know at Market Close: Jamie Dimon's the King of Wall Street

3 Things to Know at Market Close: Jamie Dimon's the King of Wall Street

Tesla's Biggest Near-Term Headwind, According to Analyst

Tesla's Biggest Near-Term Headwind, According to Analyst

Striking Options: Crude Oil Volatility and Mixed Global Economic Data

Striking Options: Crude Oil Volatility and Mixed Global Economic Data

New Trend for Gap Stock Is Down

New Trend for Gap Stock Is Down